<DOC>
	<DOCNO>NCT00296972</DOCNO>
	<brief_summary>The main purpose study compare safety , effectiveness tolerability use Pegasys Copegus people hepatitis C virus ( HCV ) genotype 1 HIV continue take HAART ( highly active antiretroviral therapy ) discontinue take HAART . Canadian guideline recommend HIV HCV treat time medication need treat two disease may interact disease treat first dependent CD4 count . In study , CD4 count must 350 cell one must stable HAART start study medication Pegasys combination Copegus .</brief_summary>
	<brief_title>Tolerability Peginterferon Plus Ribavirin Chronic Hepatitis C HIV Patients Receiving Antiretroviral Medication v Not Receiving Antiretroviral Medication</brief_title>
	<detailed_description>Since introduction highly active antiretroviral therapy ( HAART ) , liver disease secondary HCV infection become leading cause morbidity mortality HIV/HCV co-infection . The influence HCV co-infection progression HIV less clear result conflict . Studies conduct pre-HAART era find HIV/HCV co-infection influenced progression HIV-induced immunodeficiency death . Of four large study conduct HAART introduce , two suggest fast progression HIV disease presence HCV co-infection two find influence HCV co-infection overall mortality progression HIV disease . HCV may also negatively influence HIV disease indirect way , make discontinuation antiretroviral treatment frequent increase risk liver toxicity.The morbidity mortality result rapid progression HCV infection HIV-co-infected patient , particularly give advance HIV treatment improve life expectancy HIV-infected patient , support treat HCV infection patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Hepatitis C genotype 1 infection· Detectable plasma HCVRNA Roche &gt; 1000copies/ml , &gt; 600IU/ml Chronic liver disease consistent CHC infection biopsy obtain within past 24 month Patients cirrhosis incomplete cirrhosis must abdominal ultrasound , CT scan , MRI scan without evidence hepatocellular carcinoma serum AFP &lt; 100 ng/mL within 2 month randomization Patients CD4 cell count ³ 350 cell /µL Patients stable highly active antiretroviral therapy ( HAART ) least 12 week prior baseline exception patient receive didanosine HIV1 RNA &lt; 5000 copies/mL IFN , pegylated interferon , viramidine , levovirin , ribavirin therapy previous time Patients evidence active hepatitis B infection . ( presence HbsAg ) History evidence decompensated liver disease and/or ChildPugh score &gt; 5 , bleed esophageal varix , hepatic malignancy abnormal bloodwork ie absolute neutrophil &lt; 1 , Hbg &lt; 110 , Platelets &lt; 70 , creatinine &lt; 50</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>peg interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>